The authors reply

Affiliations

¹ Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA. Electronic address: Khashayar.sakhaee@utsouthwestern.edu.
² Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA.

Free article

Comment

Khashayar Sakhaee et al. Kidney Int. 2019 Aug.

Free article

. 2019 Aug;96(2):519.

doi: 10.1016/j.kint.2019.04.016.

¹ Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA. Electronic address: Khashayar.sakhaee@utsouthwestern.edu.
² Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA; Department of Internal Medicine, University of Texas Southwestern Medical Center, University of Texas, Dallas, Texas, USA.

No abstract available

Comment on

Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone.
Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Maalouf NM, et al. Kidney Int. 2019 May;95(5):1262-1268. doi: 10.1016/j.kint.2018.11.024. Epub 2019 Feb 19. Kidney Int. 2019. PMID: 30795852 Free PMC article. Clinical Trial.
Pioglitazone and nephrolithiasis.
Niu SW, He JS, You-Hsien Lin H. Niu SW, et al. Kidney Int. 2019 Aug;96(2):518-519. doi: 10.1016/j.kint.2019.04.015. Kidney Int. 2019. PMID: 31331471 No abstract available.